H.C. Wainwright lowered the firm’s price target on Verastem to $7 from $17.50 and keeps a Buy rating on the shares. The firm cites equity dilution associated with the offering and adjusting for future warrant exercises for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM: